BioSpace News Archive

Kannalife, Inc., a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Company’s Board of Advisors.

North Central Health Care has selected Cerner Corporation®, a global health care technology company, to implement its electronic health record at three multi-specialty behavioral health care facilities across Wisconsin.

Seclidemstat is currently being studied in a Phase 1/2 clinical trial for Ewing sarcoma, a rare and deadly pediatric bone cancer

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Biologics License Application (“BLA”) for Danyelza™

NuProbe, a global precision molecular diagnostics company, announces the world-wide exclusive in-license of two technologies from Rice University.

AMERI Holdings, Inc. (NASDAQ: AMRH) (the “Company”), today announced that its proposed amalgamation partner Jay Pharma Inc. (“Jay Pharma”) received institutional review board (“IRB”) approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma’s proprietary cannabidiol

Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Duchenne UK, a UK-based patient organization, are pleased to announce the launch of their joint 2020 Research Grant Call, inviting research proposals for submission and review.

Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research collaboration with the Harvard Chan Microbiome in Public Health Center (HCMPH Center), a group at Harvard T.H. Chan School

ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that the ZOLL AED 3® defibrillator received premarket approval (PMA) by the FDA for use by lay rescuers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005565/en/ ZOLL AED 3 (Photo: Business Wire) “ZOLL

- Compatibility plan includes testing representative samples of all commercially available CVCs and PICCs - Plan is designed to be conducted in parallel with the completion of the Phase 3 pivotal trial - Targeted worldwide market for Mino-Lok® is expected to reach $1.84 billion by 2028